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Abstract 
SIRT1, a homolog of yeast Sir2, is a type III NAD
+ dependent histone and protein deacetylase. 
Previous studies of mice carrying liver specific deletion of exon 4 of the Sirt1 gene revealed 
opposite responses of mutant mice to a high-fat diet in terms of fatty liver formation, which 
obscures the function of SRIT1 in liver development and lipid metabolism. To investigate this, 
we deleted exons 5 and 6 of Sirt1 in the liver by using a Cre-loxP approach. Western blot using 
an antibody to N-terminal SIRT1 does not detect a truncated protein in the liver of the mutant 
mice (Sirt1
flox5-6/flox5-6;Alb-Cre), suggesting a null mutation for SIRT1 is generated in the liver. 
Unlike the previously reported phenotypes, the Sirt1
flox5-6/flox5-6;Alb-Cre mice develop fatty liver 
under a normal feeding condition. The disease starts at two months of age and incidence 
increases as the animals become older, affecting 78% of them when they are over one year of 
age. We showed that the steatosis is accompanied by altered expression of a number of genes, 
including increased expression of ChREBP, which acts as one of the central determinants of 
lipid synthesis in the liver. This data uncovers an important role of SIRT1 in regulating lipid 
metabolism in the liver, and the SIRT1 mutant mice may serve as an animal model for studying 
human fatty liver disease and facilitate the development of effective therapeutic approach for 
the disease. 
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Introduction 
SIRT1 is a founding member of a family of 7 
Sirtuins (SIRT1-7), all of which possess NAD+ de-
pendent deacetylase activity and/or mono-ADP ri-
bosylase activity [1-4]. Previous studies revealed im-
portant functions of these genes, with a focus largely 
on SIRT1, in many biological processes including cell 
growth, apoptosis, senescence, neuronal protection, 
adaptation to calorie restriction, organ metabolism 
and disease, DNA damage response and repair, and 
tumorigenesis [1-3, 5-11]. The majority of mutant mice 
carrying targeted disruptions of SIRT1 die during 
embryonic development or at neonatal stages [8, 12, 
13]; therefore tissue-specific approaches have been 
employed to overcome the lethality and to study 
SIRT1 function in adult animals. However, mice car-
rying a liver specific disruption of SIRT1 by two dif-
ferent groups exhibited opposite phenotypes. In both 
studies, the investigators deleted exon 4 of the Sirt1 
gene by a Cre-loxP-mediated approach using an al-
bumin-Cre transgene to generate liver-specific SIRT1 
mutant mice (Sirt1flox4/flox4;Alb-Cre). The 
Sirt1flox4/flox4;Alb-Cre mice appeared normal under reg-
ular feeding conditions. However, upon feeding with 
a high fat diet, the mutant mice in the two different 
studies exhibited either accelerated [14] or attenuated 
[15] fatty liver formation when compared with con-
trols. Liver steatosis is a complex disease and may be 
affected by a variety of intrinsic and environmental Int. J. Biol. Sci. 2010, 6 
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factors [16, 17]. While the causes for this discrepancy 
are currently unclear, it is noted that the Cre-mediated 
recombination generates a truncated protein in the 
liver of the Sirt1flox4/flox4;Alb-Cre m i c e  [ 1 4 ,  1 5 ] ,  w h i c h  
may further complicate the situation. 
While investigating SIRT1 function, we gener-
ated a mutant strain carrying a Cre-mediated deletion 
of exons 5 and 6 of the Sirt1 gene in the liver. Unlike 
previously-reported phenotypes of the 
Sirt1flox4/flox4;Alb-Cre mice, our mutant mice 
(Sirt1flox5-6/flox5-6;Alb-Cre, or Sirt1LKO) gradually devel-
oped fatty liver disease even in the absence of a 
high-fat diet. Fatty liver developed when the animals 
were two months of age, and gradually increased in 
older animals. The steatosis is accompanied by in-
creased expression of carbohydrate responsive ele-
ment binding protein (ChREBP), which is a major 
regulator for lipid synthesis [16]. Thus, our data rein-
forced a critical role of SIRT1 in regulating lipid me-
tabolism in the liver.  
Results and Discussion 
To generate a Sirt1 conditional mutant allele, we 
started with an existing mutant allele that carries a 
ploxPneo gene in the intron 4 and a third loxP in intron 
6 of the Sirt1 locus [8]. Cre-mediated complete dele-
tion of loxP floxed sequence created a null allele of 
Sirt1, leading to middle gestation lethality [8]. Using a 
strategy for screening Cre-mediated incomplete re-
combination in mice [18], we successfully deleted the 
ploxPneo specifically while leaving the third loxP in-
tact, thus generating an allele that can be used for 
conditional knockout of SIRT1 (Sirt1flox5-6) (Fig. 1A, B). 
To study functions of SIRT1 in the liver, we generated 
liver- specific knockout of Sirt1 (Sirt1LKO) by crossing 
the  Sirt1flox5-6  mice with mice that carry an album 
promoter driven Cre transgene (Alb-Cre) [19] (Fig. 1C, 
D). With an antibody against N-terminus of SIRT1, we 
did not detect any truncated or short isoforms of 
SIRT1 (Fig. 1E), indicating that our Sirt1LKO mouse is a 
liver SIRT1 null animal model. 
The livers from Sirt1LKO mice were examined at 4 
time points, i.e. 2 months, 6 months, 8 months or over 
12 months after birth. At 2 months, although the livers 
of Sirt1LKO mice were histologically normal (Fig. 2A), 
some (2/7) of them have started to accumulate lipid 
droplet as revealed by Oil-Red O staining (data not 
shown). At 6 months of age, 56% (5/9) of Sirt1LKO mice 
displayed fat liver as revealed by Oil-Red O staining 
(Fig. 2B). The frequency of fatty liver was also signif-
icantly increased as the animals aged, reaching 78% 
(7/9) when they were over 1 year of age (Fig. 2C,D). In 
contrast, only 17% (2/12) of control animals exhibited 
fatty liver during the same period of time (Fig. 2D). 
Consistent with the increased lipid deposition, we 
detected marked increase of triglyceride (TG) in the 
mutant liver (Fig. 2E). Although free fatty acid (FFA) 
in serum is only slightly increased (Fig. 2F), signifi-
cant higher level of TG content was also observed in 
the serum of the mutant mice (Fig. 2G). Altogether, 
these data indicated that absence of SIRT1 in the liver 
causes fatty liver even without feeding these mice 
with high-fat diet. 
Altered signaling in a number of biological 
pathways, including glycolysis, β oxidation, fatty acid 
synthesis, TG synthesis and fat uptake, could cause 
the liver steatosis [16, 20]. To understand the under-
lying mechanism(s) for the disease, we studied gene 
expression in Sirt1LKO mice. We reasoned that what-
ever the signaling pathway changed, if it is intrinsic to 
SIRT1 deletion in the liver, it should take place when 
the mice were young. Thus, liver RNA was extracted 
from 2-month mice and real time RT-PCR was per-
formed on sets of genes that are involved in the 
pathways mentioned above. Our examination of two 
major glycolytic genes, glucokinase (Gk) and liv-
er-specific pyruvate kinase (Lpk), did not detect an 
obvious alteration in their expression (Fig. 3A). The 
investigation of genes that are involved in 
β-oxidation, esterification and fat uptake did not 
detect any evident change either (Fig. 3A). Next, we 
examined the expression of genes that are involved in 
de novo lipid synthesis. We found the mutant mice had 
elevated expression of a number of genes, including 
fatty acid synthase (FAS), acetyl-CoA carboxylase 
(ACC), and elongase of long chain fatty acids family 6 
(ELOVL6) (Fig. 3B). The liver samples from older 
Sirt1LKO mice also displayed increased expression le-
vels of these genes (Fig. 3C), indicating that the ab-
sence of SIRT1 elevated de novo lipid synthesis. Int. J. Biol. Sci. 2010, 6 
 
 
http://www.biolsci.org 
684
 
Figure 1. Generation of liver specific SIRT1 knockout mice. (A) To generate a Sirt1 conditional mutant allele, an 
existing mutant allele that carries a ploxPneo gene in the intron 4 and a third loxP in the intron 6 of the Sirt1 locus was used 
(upper panel). After breeding mice carrying the 3-loxP allele of Sirt1 gene with EIIa-Cre transgenic mice, Cre-mediated 
recombination between loxP1 and loxP2 was identified using primers 1 and 2 (P1 and P2) to screen for offspring that has the 
neo gene deleted while still keeping the loxP3 (lower panel). (B) PCR analysis to identify offspring that carry Cre-mediated 
recombination between loxP1 and loxP2 (using primers 1 and 2: ~700 bp for Sirt1
flox5-6 allele and ~640 bp for wild type allele) 
while keeping loxP3 (using primers 3 and 4: ~420 bp for mutant allele and ~360 bp for wild type allele). The first three lanes 
are liver DNA from Sirt1 
flox5-6/flox5-6 mice and these primers only detect the 700 pb and 420 bp bands, while the last two lanes 
are samples from wild type mice and only detect the 640 bp and 360 bp bands. (C) Sirt1 
flox5-6/flox5-6 mice were crossed with 
mice carrying an album promoter driving Cre transgene (Alb-Cre) to generate liver specific SIRT1 knockout mice 
(Sirt1
flox5-6/flox5-6;Alb-Cre, or Sirt1
LKO). (D) Sirt1
LKO mice were validated by PCR analysis of genomic DNA isolated from liver tissue 
with primers P1/P4 to demonstrate the deletion of exon 5 and exon 6. (E) Western blot with an antibody against SIRT1 
N-terminus to demonstrate that there is no truncated SIRT1 in our SIRT1 liver specific knockout mice. The samples were 
from 2 months old male mice. More than 20 pairs of animals were analyzed. Data from 2 pairs are shown here.  Int. J. Biol. Sci. 2010, 6 
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Figure 2. SIRT1 liver specific knockout causes liver steatosis. (A-C) H&E staining and Oil Red O staining of 2 
months (A), 6 months (B) and 14 months (C) old male mice liver respectively. (D) Oil Red O staining of 14 months old male 
liver with higher magnification. The inserted table is the summary of fatty liver cases at different age among control (Sirt1
flox5-6) 
and liver specific SIRT1 knockout (Sirt1
LKO) males. (E-G) Liver triglyceride (TG) content (E), plasma free fatty acid (FFA) 
amount (F) and plasma triglyceride (TG) content (G) of 9 months old male mice (n=11). *p<0.05. Int. J. Biol. Sci. 2010, 6 
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Figure 3. SIRT1 liver specific knockout leads to increased expression of lipid metabolism genes. (A) The 
expression of genes involved in glycolysis, β-oxidation, esterificaiton and fat uptake is not changed in the livers of Sirt1
LKO male 
mice at 2 months of age (n≥6). (B) Sirt1
LKO mice display elevated expression of FAS, ACC1 and ELOVL6 at 2 months (n≥6). 
*p<0.05. (C) At 6 months of age, the expression of FAS, ACC1, ELOVL6 and SCD1 remains increased in Sirt1
LKO mice (n≥6). 
*p<0.05. (D-E) The expression of SREBP-1c is down regulated in Sirt1
LKO mice at 2 months of age at both mRNA level (C) and 
protein level (D). (F) In vitro, deletion of SIRT1 (compare last two bars) or knocking down SIRT1 by siRNA (the first two 
bars) reduces mRNA level of SREBP-1c, while over expressing SIRT1 (middle two bars) increases SREBP-1c mRNA level. * 
p<0.01 Int. J. Biol. Sci. 2010, 6 
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Hepatic de novo lipid synthesis in general is 
under the control of two major transcriptional factors: 
sterol regulatory element binding protein-1c 
(SREBP-1c) and carbohydrate response element 
binding protein (ChREBP) [16, 21]. Evidence is 
emerging that both SREBP-1c and ChREBP are posi-
tive regulators for FAS, ACC1 and ELOVL6. These 
two master regulators have a fundamental difference: 
SREBP-1c responds to insulin signaling while 
ChREBP is totally tied with the level of hepatic glu-
cose. To our surprise, we found that SREBP-1c was 
reduced in the liver of Sirt1LKO mice at 2 months of age 
dramatically at both mRNA level and protein level 
(Fig. 3D, E). To further determine the potential rela-
tionship between SRIT1 and SREBP-1c, we quantified 
mRNA level of SREBP-1c in SIRT1 knockout, SIRT1 
knockdown by siRNA and over-expressed conditions 
in mouse embryonic fibroblast cells (MEFs) (Fig. 3F). 
Both deletion and knockdown of SIRT1 decreased the 
expression level of SREBP-1c, while over expression 
of SIRT1 up-regulated the mRNA level of SREBP-1c 
(Fig. 3F). These data indicates that insulin dependent 
lipid synthesis pathway is impaired in Sirt1LKO mice 
due to the reduced expression of SREBP-1c. At 6 
months of age, although levels of SREBP-1c mRNA 
increased to a level slightly higher that those of con-
trols (Fig. 3D), this might be caused by a feedback 
mechanism from sensing overall signaling after 
long-term deficiency of SIRT1. This phenomenon has 
been manifested well by the expression of stea-
royl-CoA desaturase-1 (SCD-1), which is a primary 
target of SREBP-1c [22]. In Sirt1LKO mice, at two month 
of age, when SREBP-1c is dramatically down regu-
lated, SCD-1 mRNA level is significantly reduced 
compared with control (Fig. 3B). However, at 6 month 
of age, when SREBP-1c displayed a tendency to be 
induced, SCD-1 mRNA level becomes significantly 
increased (Fig. 3C). 
Since CREB, C/EBP proteins and PPARγ can 
regulate genes in SREBP-1c pathway, we also ex-
amined the expression level of CREB, C/EBPα, 
C/EBPβ, C/EBPδ and PPARγ in 2-month and 
6-month old Sirt1LKO mice livers. As shown in Fig. 4A, 
even though CREB, and C/EBPβ, C/EBPδ displayed 
elevated mRNA level at 2 months of age, but this 
trend did not stay when the mutant mice got older (6 
months). Thus, we excluded them as primary effectors 
for increased lipid synthesis in Sirt1LKO mice. 
 Next, we studied ChREBP, another major tran-
scriptional factor that regulates expression of genes 
involved in fat metabolism and may be responsible 
for the increased expression of FAS, ACC1 and 
ELOVL6 [23, 24]. We detected up-regulated expres-
sion of ChREBP in the liver of both 2 months and 6 
months old Sirt1LKO mice at mRNA level (Fig. 4B) and 
protein level (Fig. 4C). Studies in MEFs demonstrated 
that deletion of SIRT1 by either knockout or knock-
down increased the expression of ChREBP by 2-3 
folds, while over-expression of SIRT1 reduced its level 
by 2 folds (Fig. 4D). Chromatin immunoprecipitation 
(ChIP) with antibodies against acetylated histone H3 
lysine 9 (Ac-H3K9) and histone H4 lysine 16 
(Ac-H4K16) revealed elevated levels of acetylation on 
H3K9 and H4K16 (Fig. 4E-G). Thus, ChREBP promo-
ter carries an open structure with increased transcrip-
tion possibility, which is consistent with the absence 
of SIRT1 deacetylase. 
In summary, we have constructed a liver specific 
knockout SIRT1 model by deleting exon5 and exon6. 
Unlike the previously described allele [14, 15], the 
mutant mice created here do not contain a smaller 
SIRT1 product. Although potential function of this 
product has not been tested, it remains possible that 
this protein, combined with different experimental 
conditions, may modify phenotypes. Nonetheless, the 
Sirt1LKO mice generated in our study develop into 
fatty liver that is accompanied by increased expres-
sion of ChREBP. The liver steatosis is developed un-
der normal feeding condition when they are relatively 
young and the symptom is worsened while the ani-
mals are getting older. This mimics the human 
non-alcoholic fatty liver disease (NAFLD), which is 
the most common cause of liver dysfunction world-
wide in human and it affects about 20 million people 
in USA [25, 26]. Thus, the Sirt1LKO mice may serve as 
an animal model for understanding mechanism of 
liver steatosis and may facilitate the development of 
effective therapeutic approaches for this disease.  
 Int. J. Biol. Sci. 2010, 6 
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Figure 4. SIRT1 liver-specific knockout leads to increased expression of ChREBP. (A) The expression of CREB, 
CEBPβ and CEBPδ is up-regulated in the liver of Sirt1
LKO male mice at 2 months of age (n≥6). *p<0.05 (B) Sirt1
LKO mice display 
consistent elevated mRNA level of ChREBP at both 2 months and 6 months of age (n≥6). *p<0.05 . (C) At 2months of age, 
Sirt1
LKO mice contain higher ChREBP protein level. (D) In vitro, deletion of SIRT1 (last two bars) or knocking down SIRT1 by 
siRNA (first two bars) increased the mRNA level of ChREBP, while over expressing SIRT1 (middle two bars) reduces 
ChREBP mRNA level. * p<0.01. (E-G) Chromatin Immunoprecipitation (ChIP) assay demonstrates deletion of SIRT1 leads to 
increased acetylation of histone H3K9 and histone H4K16 on 3 fragments (365-539, 984-1173 and 1614-1752) upstream of 
starting codon ATG of ChREBP promoter. Int. J. Biol. Sci. 2010, 6 
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Materials and Method 
Generation of Sirt1 floxed allele and liver specific 
Sirt1 deletion animals 
Mice that carry 3 loxP sites (a ploxPneo [27] in 
intron 4 and the third loxP in intron 6) were crossed 
with EIIa-Cre transgenic mice [28] to delete the 
ploxPneo using a protocol as described [18]. The re-
sulting mice carrying the floxed exon 5 and exon 6 of 
the Sirt1 gene were bred with Albumin-Cre transgenic 
mice [19] to obtain Sirt1+/flox5-6;Alb-Cre strain. After-
wards, males and females of Sirt1+/flox5-6;Alb-Cre were 
intercrossed to generate Sirt1flox5-6/flox5-6;Alb-Cre mice 
that carry a liver specific deletion of SIRT1 (Sirt1LKO) 
and control mice with various genotypes. These mice 
are in a mixed genetic background of 129/FVB/Black 
Swiss and are genotyped with the following primers: 
Floxed  Sirt1 gene: p1- 5' CTT CCT TGC CAC 
AGT CAC TC 3'; p2- 5' CAT CTA AAC TTT GTT GGC 
TGC 3'; p3- 5' GTG GAG GTC AGA AGA TCA ACC 
3'; p4- 5' CAG ACA TGC AGG CAA ACA CCC 3'. 
Alb-Cre: Forward- 5’ CCT GTT TTG CAC GTT CAC 
CG 3’; Reverse- 5’ ATG CTT CTG TCC GTT TGC CG 
3’. Recombined allele was genotyped with p1 and p4. 
All experiments were approved by the Animal Care 
and Use Committee of the National Institute of Di-
abetes, Digestive and Kidney Diseases (ACUC, 
NIDDK).  
Triglyceride (TG) and Free Fatty Acid (FFA) 
measurement 
Liver was used for triglyceride content mea-
surements with RA method. Serum TG and FFA were 
measured by Metabolic Core Facility of NIDDK. 
Western blot analysis 
Western blot was carried out with Licor (Lincoln, 
Nebraska) utilizing antibodies against SIRT1 (Ups-
tate), SREBP-1c (Abcam) and ChREBP (Santa Cruz).  
QRT-PCR 
Liver tissue was dissected and immediately put 
into RNALater Solution (Ambion Inc.). Total RNA was 
isolated with STAT-60TM (TEL-TEST, Inc.) from these 
l i v e r  t i s s u e s  a n d  c l e a n e d  u p  w i t h  R N e a s y  M i n i  K i t  
(Qiagen). cDNA was synthesized with Cells-to-cDNA 
TMII (Ambion Inc.). Quantitative RT-PCR was per-
formed using a SYBR green PCR Master Mix (Applied 
Biosystems) and 7500 Real Time PCR (Applied Bio-
systems). The primers are as following:  
SREBP-1 F: 5’ AAG CAA ATC ACT GAA GGA 
CCT GG 3’, R 5’ AAA GAC AAG GGG CTA CTC 
TGG GAG 3’; 18S(RAT, MUS HU) F: 5’ AGT CCC 
TGC CCT TTG TAC ACA 3’, R: 5’ CGA TCC GAG 
GGC CTC ACT A 3’; ChREBP F: 5’ 
GCATCCTCATCCGACCTTTA 3’, R: 5’ 
GATGCTTGTGGAAGTGCTGA 3’. 
Histology and oil red O staining 
Tissue was fixed in 10% neutral-buffered forma-
lin (VWR) at 4oC overnight, dehydrated through a 
graded alcohol series, xylene and paraffin, and then 
embedded in paraffin. Sections of 5 μm were prepared 
for H&E. For Oil Red O staining, liver tissues, which 
were frozen in OCT compounds, were cut at 5 μm, 
mounted on slides and allowed to dry for 1-2 hrs. The 
sections were fixed with 10% formalin for 10 min and 
then the slides were rinsed with PBS (PH 7.4). After 
air dry, the slides were placed in 100% propylene 
glycol for 2 min, and stained in 0.5% Oil Red O solu-
tion in propylene glycol for 30 min. The slides were 
transferred to an 85% propylene glycol solution for 1 
min., rinsed in distilled water for 2 changes, and 
processed for hematoxylin counter staining. 
Transfection 
Mammalian expression vector pUSE-SIRT1 was 
purchased from Upstate. Mouse SIRT1 siRNAs were 
used as previously (Mol Cell paper). All the transfec-
tions were performed with LipofectaminTM 2000 (in-
vitrogen) on MEF cells. 
Chromatin immunoprecipitation (ChIP) analysis 
For ChIP analysis of cultured cells, cells were 
cross-linked with a final concentration of 1% formal-
dehyde for 15 min at RT, quenched with 125 mM of 
glycine for 5 min, and were suspended with 1 ml of 
lysis buffer (50 mM Tris-Cl at pH7.5, 150mM NaCl, 
5mM EDTA, 1% Triton X-100, 0.5% NP-40) supple-
mented with protease inhibitors for 1 min at 4°C, and 
sonicated extensively. After centrifugation, the su-
pernatant was used for ChIP with antibodies against 
Ac-H3K9 or AC-H4K16 together with rabbit IgG as a 
control. Final immunoprecipitated DNA was ana-
lyzed by Real Time PCR. 
Acknowledgment  
We thank members of Deng lab for their helpful 
discussion of this work and Dr. Cristine Chisholm for 
critical reading of this manuscript. This work was 
supported by the Intramural Research Program of the 
National Institute of Diabetes, Digestive and Kidney 
Diseases, National Institutes of Health, USA. 
Conflict of Interests 
The authors have declared that no conflict of in-
terest exists. Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
690
References 
1.   Saunders LR, Verdin E. Sirtuins: critical regulators at the cros-
sroads between cancer and aging. Oncogene. 2007; 26: 
5489-5504. 
2.   Lavu S, Boss O, Elliott PJ, et al. Sirtuins--novel therapeutic tar-
gets to treat age-associated diseases. Nat Rev Drug Discov. 
2008; 7: 841-853. 
3.    Finkel T, Deng CX, Mostoslavsky R. Recent progress in the 
biology and physiology of sirtuins. Nature. 2009; 460: 587-591. 
4.   Guarente L. Sirtuins in aging and disease. Cold Spring Harb 
Symp Quant Biol. 2007; 72: 483-488. 
5.   Vaquero A, Scher M, Erdjument-Bromage H, et al. SIRT1 regu-
lates the histone methyl-transferase SUV39H1 during hete-
rochromatin formation. Nature. 2007; 450: 440-444. 
6.   Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? 
Int J Biol Sci. 2009; 5: 147-152. 
7.   Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, 
SIRT1, and Survivin during BRCA1-associated tumorigenesis. 
Mol Cell. 2008; 32: 11-20. 
8.   Wang RH, Sengupta K, Li C, et al. Impaired DNA damage re-
sponse, genome instability, and tumorigenesis in SIRT1 mutant 
mice. Cancer Cell. 2008; 14: 312-323. 
9.    Kim HS, Patel K, Muldoon-Jacobs K, et al. SIRT3 is a mito-
chondria-localized tumor suppressor required for maintenance 
of mitochondrial integrity and metabolism during stress. Can-
cer Cell. 2010; 17: 41-52. 
10.  Jacobs KM, Pennington JD, Bisht KS, et al. SIRT3 interacts with 
the daf-16 homolog FOXO3a in the Mitochondria, as well as 
increases FOXO3a Dependent Gene expression. Int J Biol Sci. 
2008; 4: 291-299. 
11.    Byles V, Chmilewski LK, Wang J, et al. Aberrant cytoplasm 
localization and protein stability of SIRT1 is regulated by 
PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci. 
2010; 6: 599-612. 
12.    McBurney MW, Yang X, Jardine K, et al. The mammalian 
SIR2alpha protein has a role in embryogenesis and gametoge-
nesis. Mol Cell Biol. 2003; 23: 38-54. 
13.  Cheng HL, Mostoslavsky R, Saito S, et al. Developmental de-
fects and p53 hyperacetylation in Sir2 homolog 
(SIRT1)-deficient mice. Proc Natl Acad Sci U S A. 2003; 100: 
10794-10799. 
14.  Chen D, Bruno J, Easlon E, et al. Tissue-specific regulation of 
SIRT1 by calorie restriction. Genes Dev. 2008; 22: 1753-1757. 
15.    Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific 
deletion of SIRT1 alters fatty acid metabolism and results in 
hepatic steatosis and inflammation. Cell Metab. 2009; 9: 
327-338. 
16.  Postic C, Girard J. Contribution of de novo fatty acid synthesis 
to hepatic steatosis and insulin resistance: lessons from geneti-
cally engineered mice. J Clin Invest. 2008; 118: 829-838. 
17.  Savage DB, Semple RK. Recent insights into fatty liver, meta-
bolic dyslipidaemia and their links to insulin resistance. Curr 
Opin Lipidol. 2010; 21: 329-336. 
18.  Xu X, Li C, Garrett-Beal L, et al. Direct removal in the mouse of a 
floxed neo gene from a three-loxP conditional knockout allele 
by two novel approaches. Genesis. 2001; 30: 1-6. 
19.  Yakar S, Liu JL, Stannard B, et al. Normal growth and devel-
opment in the absence of hepatic insulin-like growth factor I. 
Proc Natl Acad Sci U S A. 1999; 96: 7324-7329. 
20.  Kim H-S, Xiao C, Wang R-H, et al. Hepatic-specific disruption of 
SIRT6 in mice results in fatty liver formation due to enhanced 
glycolysis and triglyceride synthesis. Cell metabolism. 2010; 12: 
224-236. 
21.  Strable MS, Ntambi JM. Genetic control of de novo lipogenesis: 
role in diet-induced obesity. Crit Rev Biochem Mol Biol. 2010; 
45: 199-214. 
22.    Le Lay S, Lefrere I, Trautwein C, et al. Insulin and ste-
rol-regulatory element-binding protein-1c (SREBP-1C) regula-
tion of gene expression in 3T3-L1 adipocytes. Identification of 
CCAAT/enhancer-binding protein beta as an SREBP-1C target. 
J Biol Chem. 2002; 277: 35625-35634. 
23.  Denechaud PD, Bossard P, Lobaccaro JM, et al. ChREBP, but not 
LXRs, is required for the induction of glucose-regulated genes 
in mouse liver. J Clin Invest. 2008; 118: 956-964. 
24.    Yamashita H, Takenoshita M, Sakurai M, et al. A glu-
cose-responsive transcription factor that regulates carbohydrate 
metabolism in the liver. Proc Natl Acad Sci U S A. 2001; 98: 
9116-9121. 
25.  Rogers CQ, Ajmo JM, You M. Adiponectin and alcoholic fatty 
liver disease. IUBMB Life. 2008; 60: 790-797. 
26.    Ahmed MH, Byrne CD. Current treatment of non-alcoholic 
fatty liver disease. Diabetes Obes Metab. 2009; 11: 188-195. 
27.  Deng CX, Xu X. Generation and analysis of Brca1 conditional 
knockout mice. Methods Mol Biol. 2004; 280: 185-200. 
28.  Lakso M, Pichel JG, Gorman JR, et al. Efficient in vivo manipu-
lation of mouse genomic sequences at the zygote stage. Proc 
Natl Acad Sci U S A. 1996; 93: 5860-5865. 